How a Soft Diagnosis Becomes a Hard Headline
Two of eleven. That's the entire bar for a diagnosis now making headlines as "cannabis addiction."
Latest
New Genetics Study Splits "Cannabis Use" From "Cannabis Use Disorder"
Roughly one in ten people who try cannabis goes on to develop cannabis use disorder (CUD). What separates that minority from everyone else who uses cannabis without it becoming a problem has never been well understood.
The Chronic Illness Trap: Why NSW’s New Medical Cannabis Driving Laws Are a Backdoor Ban
These changes do not liberate medicinal cannabis users; instead, they establish a digital surveillance framework that explicitly targets and bans people with chronic illnesses from driving.
The Study Said Psychosis Rates Were Equal to Placebo. Most Outlets Left That Part Out.
A major Lancet Psychiatry meta-analysis on cannabinoids and mental health was reported accurately on some points, incompletely on others, and misleadingly on at least one finding that cuts against a well-established media narrative. Often, all three occurred in the same article.`
Running on Empty: Why Hemp Derived Biodiesel Deserves a Serious Place in Australia's Fuel Future
"Australia cannot refinery-build its way out of this crisis quickly enough. But it can grow its way toward a more resilient position — if it chooses to."
New Preclinical Research Explores the Endocannabinoid System in Alzheimer's Disease and Chronic Pain
The endocannabinoid system plays a modulatory role in both pain processing and neurological function. It is altered in both Alzheimer's disease and chronic pain states, making it an area of active research interest.
Two Veterans, Same Diagnosis, Different Rules: DVA's New Medicinal Cannabis Framework Creates a Two-Tier System
For a veteran in outback Queensland newly diagnosed with a terminal illness, "find a specialist and attend in person first" is not a neutral administrative requirement. It is a genuine barrier to care, arriving at the worst possible time.
Cannabis Shows Promise for Advanced Pancreatic Cancer Symptom Management
The study was supported by philanthropic funding to the HealthPartners Cancer Research Centre, with cannabis products provided by Vireo Health (GreenGoods, Minnesota).
Victorian Medicinal Cannabis Driving Trial Reaches Key Milestone
Recruitment of adults with medicinal cannabis prescriptions has now concluded.
Trump Executive Order Signals Major Shift in US Medical Cannabis Policy
Schedule III classification would recognise cannabis as having accepted medical use and lower abuse potential than Schedule I or II substances.
New York Study Links Medical Cannabis to Reduced Opioid Use
The 22% reduction in opioid use may seem modest, but researchers emphasise this aligns with current clinical recommendations for gradual opioid tapering over extended periods rather than rapid cessation.
Australia's Hemp Trials Reveal Hard Truths: Industry at Critical Crossroads
The most alarming finding from the trials is the catastrophic variability in imported seed quality.
Early Leaf Scans Could Revolutionise Cannabis Production
The implications for Australia's emerging cannabis industry are substantial.
CNX Therapeutics Acquires Sativex in Strategic CNS Portfolio Expansion
Sativex represents the first plant-derived cannabinoid medicine approved by a medicines regulator, a distinction that underscores its pioneering role in legitimising cannabis-based therapeutics.
The Cannabis Paradox: How Australia's Medical Market Boom Became a Domestic Industry Crisis
The industry's 38 tonnes of unsold inventory isn't just an economic problem. It's karma.
Cann Group Secures Major Debt Restructure and $9M Capital Raise
The debt forgiveness of $54.7 million represents an 81% reduction in the company's debt and will increase Cann Group's net assets by approximately $60 million.
tga
From Prohibition to Home Grows: Lessons from Germany's Cannabis Act for Australia's Medical Cannabis Crisis
The contrast between Germany's success and Australia's stagnation raises a fundamental question: what structural differences enable one country to achieve rapid market transformation while another remains locked in gatekeeping and corporate control?
tga
The High Cost of Relief: How Medical Cannabis Pricing Leaves Patients Behind
As health bodies call for crackdown on rogue operators, affordability crisis goes unaddressed.
tga
A Guide for Medicinal Cannabis Users on Completing the TGA Unapproved Product Survey
The Reviewing the Safety and Regulatory Oversight of Unapproved Medicinal Cannabis Products consultation commenced on 11 August 2025 and will close on 7 October.
Ecofibre Limited (ASX: EOF) delisted from the ASX
Ecofibre Limited was an Australian biotechnology company focused on hemp-derived products and technologies. The company listed on the ASX on March 29, 2019, through an IPO that raised $20 million at $1 per share, giving it a market capitalization of $309 million on listing¹. The business was headed by rich-lister
human rights
The Home Cultivation Gap: Comparing Medical Cannabis Access Rights in Australia and Canada
The prohibition creates a two-tiered system where access depends on wealth. Canadian patients can grow unlimited plants based on prescription. Low-income patients aren't excluded due to cost barriers.
OPINION
TGA's Medical Cannabis 'Safety Review': Why Patients Should Be Concerned About Proposed Changes
The consultation does not address home cultivation as a potential solution to affordability concerns, despite this approach being adopted in countries like Canada and several European nations.
australia
Fatal Fungal Contamination Highlights Critical Gap in Medical Cannabis Regulation
A groundbreaking study has provided the first definitive proof that legal medical cannabis can be a deadly source of infection for vulnerable patients.
anthocyanins
Temperature's Impact on Cannabis: New Research Reveals Optimal Growing Conditions for Purple Strains
The research suggests that cannabis cultivators face a trade-off when growing purple varieties.
OPINION
Double the Road Toll, Half the Attention: How Restrictive Cannabis Guidelines May Worsen Australia's Overdose Crisis
Australia's approach to road safety offers valuable lessons for drug policy.
thailand
Thailand’s Cannabis Flip-Flop: Legalisation’s Political Ping-Pong
This duality—strict law, informal leniency—offers a glimpse into what cannabis may become in Thailand: legal enough to use, risky enough to sensationalise.
thailand
Thailand’s Prescription-Only Pivot: A Costly Backstep for Cannabis Reform
Thailand’s Ministry of Public Health estimates 23,000 alcohol-related deaths per year, costing over 1% of GDP. Contrast to cannabis...
420
Roy Morgan Drops Article 420—and It's All About Weed Legalisation
“Australia’s debate on marijuana legalisation continues to evolve. With nearly half of Australians now in favour, the national mood has shifted significantly over the past decade.”
privacy
Medical Cannabis Privacy Gaps Leave Patient Data at Risk
The use of standard web forms and international platforms for collecting such sensitive data raises questions about whether providers are taking adequate steps to protect patient information.
Cann Group
Cann Group makes a request for trading halt.
Cann Group requested that the ASX grant a trading halt pending an announcement to be made by the Company, to the market, regarding the Company’s capital raising activities.
Whyalla
Whyalla's Green Horizon: Pioneering a Small Business Revolution Through Cannabis
The vision is simple: a cannabis sector structured to prioritize small-scale operators.
xmas
All I Want for Christmas is Legal Home Grow
All I want for Christmas is the right to grow, Not paying through the nose for what I sow. While others tend their garden spots with care, My medicine's locked behind red tape and prayer. These clinic fees are robbing us outright, With prices soaring to a ridiculous